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ABSTRACT
Background
Randomized clinical trials of methadone maintenance have found that on average high daily
doses are more effective for reducing heroin use, and clinical practice guidelines recommend
60 mg/d as a minimum dosage. Nevertheless, many clinicians report that some patients can be
stably maintained on lower methadone dosages to optimal effect, and clinic dosing practices
vary substantially. Studies of individual responses to methadone treatment may be more easily
translated into clinical practice.
Methods and Findings
A volunteer sample of 222 opioid-dependent US veterans initiating methadone treatment
was prospectively observed over the year after treatment entry. In the 168 who achieved at
least 1 mo of heroin abstinence, methadone dosages on which patients maintained heroin-free
urine samples ranged from 1.5 mg to 191.2 mg (median ¼ 69 mg). Among patients who
achieved heroin abstinence, higher methadone dosages were predicted by having a diagnosis
of posttraumatic stress disorder or depression, having a greater number of previous opioid
detoxifications, living in a region with lower average heroin purity, attending a clinic where
counselors discourage dosage reductions, and staying in treatment longer. These factors
predicted 42% of the variance in dosage associated with heroin abstinence.
Conclusions
Effective and ineffective methadone dosages overlap substantially. Dosing guidelines should
focus more heavily on appropriate processes of dosage determination rather than solely
specifying recommended dosages. To optimize therapy, methadone dosages must be titrated
until heroin abstinence is achieved.
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Methadone maintenance is one of the most highly
researched and evidence-based treatments for illicit drug
dependence. Randomized trials demonstrate that prescribing
higher dosages of methadone leads to greater reductions in
heroin use in opioid-dependent patients [1–4]. These ﬁndings
support recommendations that methadone maintenance
patients receive daily dosages of over 60 mg per day [5].
Yet, some clinicians debate these recommendations and insist
that many patients have positive outcomes with lower dosages
[6]. Consequently, some clinicians reject the research-based
recommendations as inconsistent with their clinical experi-
ence, and methadone dosing practices vary widely [7,8].
Research and clinical evidence may both be informative.
Randomized trials investigate mean population response to a
given dosage of methadone, whereas clinicians treat individ-
uals. Examining mean response may de-emphasize the range
of individual responses in the population. Additionally, when
these studies ﬁnd that higher dosages of methadone produce
greater reductions in heroin use, they tell us that there is a
subpopulation of patients who require the higher dosage;
they do not provide information about the lowest effective
dosage for individuals. Although randomized trials are useful
for identifying the active range of the dose response curve for
drug effects, they do not specify the optimal dosage for any
given individual.
Studies of individual responses to methadone dosages have
high potential for translation into clinical practice. Under-
standing the typical range of dosages over which patients
respond may guide physicians in their prescribing practices.
Identifying factors related to response at higher or lower
dosages may help clinicians predict appropriate dosages for
individuals.
Needing a higher dosage of methadone to eliminate heroin
use indicates a tolerance to the effects of opioids. Basic
science studies suggest a number of factors that may inﬂuence
individual differences in opioid tolerance, and these were
used to guide selection of measured variables in this study.
For example, more days of exposure to opioids and higher
opioid dosages have been associated with increased opioid
tolerance [9–11]. More counterintuitively, withdrawal from
opioids may produce sensitization of opioidergic neuronal
pathways that may later manifest as opioid tolerance if opioid
use is reinstated [12,13]. Genetic background also may modify
the development of tolerance [14]. Finally, disease states,
especially diseases that affect opioidergic systems, may
encourage opioid tolerance or sensitivity. For example, pain
disorders produced by nerve injury are known to increase
tolerance to the analgesic effects of opioids [15,16], and
opioid-dependent patients with Axis I psychiatric diagnoses
generally need higher methadone dosages [17]. There is
indication of opioidergic changes in depression and post-
traumatic stress disorder (PTSD) as well: decreased opioider-
gic transmission has been associated with sadness [18], case
studies have shown that opioids reduce depression symptoms
in some patients [19,20], and PTSD is associated with
enhanced release of endogenous opioids [21–23].
Treatment delivery factors might also inﬂuence the need
for higher dosages of methadone. For example, counseling
services might reduce drug craving and thus decrease the
dosage of methadone needed to produce abstinence. Treat-
ment delivery factors might also limit the population of
patients who receive a high enough dosage to abstain. At a
clinic that discourages the use of higher methadone dosages,
only patients who have lower methadone needs may achieve
abstinence.
Factors associated with opioid tolerance have not been well
studied in human patients. Determining which individual and
treatment delivery variables are associated with increased
methadone need in real-life clinical samples will inform the
therapeutic use of opioids.
Here we examine methadone dosing practices at eight
methadone maintenance clinics run in cities across the
United States by the Veterans Health Administration (VA).
First, we examined the methadone dosages at which patients
stopped heroin use and then compared these effective dosing
practices to overall dosing practices at VA clinics. Second, we
investigated variables associated with individual differences
in the methadone dosage at which each patient achieved
heroin abstinence to identify factors that contribute to
medication tolerance in opioid-dependent patients.
Methods
Recruitment
Patients were recruited through opioid substitution treat-
ment programs located in eight cities throughout the United
States. This study is part of the Multi-Site Opioid Substitution
Treatment (MOST) study [24]. The MOST study was designed
to examine differences in patient outcome based upon
naturalistic differences in treatment provision. Thus, eight
clinic sites were chosen based on their typical treatment
practices. Four sites (high guideline-adherent sites) regularly
dosed patients above the recommended 60 mg/d minimum
methadone dosage; the other four (low guideline-adherent
sites) dosed a signiﬁcant percentage of patients below the
recommended 60 mg/d level.
All MOST study procedures were approved by the Institu-
tional Review Board (IRB) of Stanford University and each
participating VA medical center (see Protocol S1). All
patients provided written informed consent (see Protocol
S2). Patients completed a structured interview by telephone
at treatment entry and 6 and 12 mo after the start of
treatment. Additionally, patients’ medical records were
accessed for the duration of the study period.
Sample
Patients in the MOST study were 254 veterans initiating
methadone/levo-a-acetyl-methadol (LAAM) treatment be-
tween November 2000 and October 2001. Although 267
patients agreed to participate, some dropped out of treat-
ment before receiving a single methadone dose or completing
their baseline interview; these participants’ data are excluded
from this analysis. During the 30 d prior to entering
treatment, 86.7% used heroin, 16.1% used illicitly obtained
opioid medications, 49.4% used cocaine, 45.9% used alcohol,
21.6% used cannabis, and 10.2% used illicitly obtained
sedatives. Historically, 66.8% reported regular use of only
heroin, 30.9% reported regular use of heroin and illicit
prescription opioids, and 2.3% reported only regular use of
illicit prescription opioids. Patients were starting opioid
substitution treatment at the time of study entry and thus
received low initial dosages that were titrated up through the
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abstinence, 55% of patients did not change dosage, 16%
decreased dosage, and 29% increased dosage by more than 5
mg during the period in which they maintained abstinence.
Several of the participating clinics also offered opioid
substitution with LAAM; typically, LAAM was used in
combination with methadone to eliminate the need for
patients to come to clinic over weekends. Over the course of
treatment, 87.4% of patients received only methadone, 2.4%
of patients received only LAAM, and 10.2% of patients
received both methadone and LAAM during the course of
treatment. Data were originally analyzed in two ways: (1)
excluding all patients who received any LAAM, and (2)
including the whole sample by converting LAAM dosages to
methadone equivalents. The conclusions of both analyses
were identical. Because LAAM is no longer manufactured, we
present the results from the subpopulation of patients who
received only methadone (analysis of the entire population is
available upon request from the corresponding author). Thus,
the ﬁnal sample consisted of 222 enrolled patients, 168 of
whom achieved at least 1 mo of heroin abstinence and were
included in the analysis of factors predicting the dosage of
methadone that was effective.
Measures
Patients completed the Addiction Severity Index (ASI [25])
and the SF-36V [26] by telephone interview with trained staff
members. Data on participants’ visits to the VA health care
system from October 2000 through September 2003 were
downloaded from the national VA databases. Patients’
medical and psychiatric diagnoses were extracted from these
databases, based upon ICD-9 codes assigned during each
medical visit. Patients’ dose of methadone for each day in
treatment and urinalysis test results were obtained. Case
managers of patients in the study were surveyed with an
81.6% response rate regarding their opinions on methadone
dosing practices. Questions about case managers’ likelihood
of suggesting a dosage decrease or detoxiﬁcation for an
abstinent patient were averaged at the clinic level to provide
a measure of tendency to discourage use of high dosages at
each clinic.
Urinalysis results were obtained from patient medical
records. Because this was an observational study, urine
screening was conducted at the discretion of the participat-
ing clinics, and timing and frequency of testing varied across
patients. However, all clinics required that a minimum one
urine screen per month be conducted on each patient. The
mean number of urine screens per month was 2.86, the
median was 4, and the range was 1–13.
Effective dosages were calculated for each patient who had
at least 1 mo of abstinence from heroin based upon urinalysis
results (i.e., 1 mo where urine tests were performed, and all
urine tests were negative for illicit opioids). Mean dosage of
methadone was calculated for each month of heroin
abstinence for each patient. For patients who had more than
1 mo of abstinence, effective dosage was averaged over
abstinent months. Because of concern that differences in
treatment trajectory (e.g., attempts to reduce dosage) after
patients achieved abstinence might alter study ﬁndings, all
analyses were also run using average dosage over the ﬁrst
month of abstinence as a measure of effective dosage. The
dosage during the ﬁrst month of abstinence was highly
correlated with the mean dosage over all abstinent months
(Pearson’s correlation coefﬁcient ¼ 0.868, p , 0.001), and
using ﬁrst month dosages did not alter the ﬁndings of the
study. Thus, only results for mean dosage over all abstinent
months are presented.
The amount of heroin used per day was estimated from
self-reported pretreatment monthly cost of drug use, using
average heroin price and purity data from the year of the
study for each locality [27] and correcting for route of
administration [28]. In this sample, heroin was administered
intravenously by 68%, nasally by 30%, via smoking by 1%,
and via nonintravenous injection by 1%.
Data Analysis
To examine effective versus actual dosing practices,
cumulative dosage histograms were created for (1) the
subpopulation that had at least 1 mo abstinence from heroin,
(2) the subpopulation that never had a month of abstinence
from heroin, (3) the subpopulation that attended a clinic with
high guideline adherence, (4) the subpopulation that
attended a clinic with lower guideline adherence.
In the subpopulation that achieved at least 1 mo of
abstinence from heroin (n ¼ 168), Pearson’s correlation
coefﬁcients (for continuous variables) or point biserial
correlation coefﬁcients (for dichotomous variables) were
assessed to identify associations between the dosage received
while abstinent from heroin and potential tolerance-related
factors. A multivariate linear regression model assessed
factors that were associated with the dosage at which a
patient abstained, controlling for multiple predictors simul-
taneously.
Results
Description of Effective and Actual Dosing Practices
One hundred sixty-eight patients had at least 1 mo of
abstinence from heroin. Effective methadone dosages ranged
from 1.5 to 191.2 mg, the median effective dosage was 69 mg
(Figure 1). Notably, 38% of patients who were heroin
abstinent for a month did so on less than 60 mg methadone
(i.e., below the minimum daily dosage recommended in
clinical practice guidelines). In contrast, 16% of patients
required over 100 mg. The 25% of patients who did not
achieve abstinence received a mean dosage of 61 mg
methadone (range: 20–150 mg; median: 60 mg). Of patients
who did not achieve abstinence, 45.6% received over 60 mg
methadone.
Mean daily dosages of methadone for patients in treatment
ranged from 30 to 167 mg (median: 76.3 mg) at high
guideline-adherent sites (n ¼ 134) and from 20 to 100 mg
(median: 59.7 mg) at low guideline-adherent sites (n ¼ 88).
Mean daily dosages received by patients who did not
abstain from heroin use and mean daily dosages at low
guideline-adherent sites were left-shifted on the cumulative
dosage histogram as compared to effective dosages, suggest-
ing that these patients were being dosed lower than necessary.
This difference was particularly pronounced in the higher
dosage ranges. In contrast, dosages at high guideline-
adherent sites were right-shifted as compared to effective
dosing, suggesting that patients were receiving just slightly
higher dosages than those given to patients who achieved
abstinence. This variation from effective dosing practices is
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low guideline-adherent sites. Patients who attended high
guideline-adherent clinics had signiﬁcantly lower rates of
heroin use at follow-up [24].
Correlations between Patient Factors and Methadone
Tolerance
To determine factors associated with tolerance to the
effects of methadone on heroin use, we examined whether
quantity and frequency of drug use, experience of opiate
withdrawal, family history of substance abuse, disease states,
or treatment delivery factors were correlated with the dosage
of methadone at which patients achieved heroin abstinence
(Table 1).
Use-Dependent Factors
Quantity and frequency of use. Recent frequency of heroin
use, the number of years that heroin had been used, and
estimates of the amount of heroin used per day were not
associated with effective methadone dosing levels. Higher
local purity of heroin was associated with lower effective
methadone dosage; this association was the opposite of
common predictions.
Withdrawal. Brief periods of withdrawal from opioids
increase opioid tolerance in basic science studies [12,13]. We
expect that opioid detoxiﬁcation treatments constitute a
signiﬁcant percentage of the major withdrawal episodes that
patients have experienced. We found that the number of
previous drug detoxiﬁcation treatments experienced tended
to correlate with the dosage of methadone needed to abstain
from heroin. As expected, the number of previous ethanol
detoxiﬁcation treatments was not correlated with the
effective methadone dosage.
Individual Differences
Family history. Although we do not have any measure of
opioid tolerance in family members, this study did collect
patient-reported data on family history of drug and alcohol
problems. Having a parent with a drug or alcohol problem
was not associated with the effective methadone dosage.
Disease States
Chronic pain. Chronic pain states, such as neuropathy,
have been associated with analgesic tolerance to opioid
medications [15,16]. To determine if chronic pain conditions
increase tolerance to methadone’s ability to prevent heroin
use, we examined the association between reported pain
levels and diagnoses of chronic pain conditions and effective
methadone dosage. The severity of pain experienced in the
past 4 wk or having a diagnosis of a chronic pain condition
was not correlated with the effective dosage of methadone.
PTSD. Having a recent diagnosis of PTSD was strongly
correlated to the effective methadone dosage. This associa-
tion did not hold for other anxiety disorders. Similarly, a
recent or lifetime history of emotional, physical, or sexual
abuse was not related to methadone tolerance, suggesting
that methadone tolerance was related to PTSD, not trauma
experience.
Depression. We examined whether depressive symptoma-
tology or diagnosis was related to methadone dosing needs.
Self-reported depression in the past 30 d and having a recent
diagnosis of clinical depression correlated positively with
effective dosage. However, self-reported depression experi-
enced throughout the lifetime was not correlated with
effective methadone dosage.
Schizophrenia. As a control, we examined whether mental
health disorders for which speciﬁc opioid contributions have
not been implicated were related to effective methadone
dosage. Schizophrenia was not signiﬁcantly correlated with
effective dosage of methadone.
Treatment delivery factors. Patients attending clinics
designated as high guideline-adherent by the MOST study
maintained abstinence on higher dosages of methadone
(high: 77.0 6 30.5 mg; low: 52.4 6 24.7 mg; p , 0.001). To
identify speciﬁc treatment factors contributing to this
correlation, we examined the relationship of effective dosage
with length of treatment, number of counseling visits,
satisfaction with treatment, and the tendency of a clinic’s
counselors to encourage abstinent patients to reduce or
eliminate their dosage of methadone. Patients who stayed in
treatment longer, received more counseling visits, and
Figure 1. Cumulative Dose Histogram Depicting the Proportion of Patients at or below a Given Methadone Dose (in mg)
Black line: methadone doses received while patients maintained heroin abstinence (n ¼ 168).
Gray line: average methadone doses received by patients who never achieved heroin abstinence (n ¼ 54).
Black dashed line: average methadone doses received by patients at low guideline-adherence clinics (n ¼ 88).
Gray dashed line: average methadone doses received by patients at high guideline-adherent clinics (n ¼ 134).
DOI: 10.1371/journal.pmed.0030080.g001
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reduction received higher methadone dosages during periods
of abstinence (Table 1).
Predictors of methadone tolerance. To determine the
predictive value of the above factors, patient variables
signiﬁcantly associated with methadone dosage were included
in a multivariate linear regression model with effective
methadone dosage as the dependent variable. Because the
study examined patient outcomes from sites speciﬁcally
chosen for their differences in treatment practices, a variable
encoding whether the patient attended a high or low
guideline-adherent treatment clinic was included in the
model. Whether the clinic generally followed treatment
guidelines, the number of previous drug detoxiﬁcation
treatments the patient had completed, whether the patient
had a diagnosis of PTSD or depression, and the local purity of
heroin predicted the dosage at which patients abstained from
heroin use (R
2 ¼ 0.335, p , 0.001). To assess which aspects of
guideline adherence were related to effective methadone
dosing, we replaced the variable encoding guideline-adher-
ence rate with treatment-level variables found to correlate
with effective dosage. The modiﬁed model better predicted
the effective methadone dosage (R
2 ¼ 0.423, p , 0.001). The
patients who remained in methadone maintenance treatment
for a longer period of time and attended clinics where
counselors reported not favoring dosage reductions in
abstinent patients received higher effective methadone
dosages. The number of counseling visits attended was
correlated with the length of time patients stayed in treat-
ment and did not additionally predict effective methadone
dosage (p . 0.05). Having a diagnosis of PTSD increased
effective methadone dosage by 12.1 mg (95% conﬁdence
i n t e r v a l :3 . 4 – 2 0 . 8m g ) .Ad i agnosis of depression also
increased effective methadone dosage by 14.1 mg (95%
conﬁdence interval: 5.6–22.6 mg). Each previous drug
detoxiﬁcation episode increased the dosage of methadone
at which patients abstained from heroin by 0.9 mg (95%
conﬁdence interval: 0.1–1.7 mg). For every 10% increase in
local heroin purity, the methadone dosage needed to
maintain abstinence decreased by 4.0 mg (95% conﬁdence
interval:  6.8 to  1.2 mg). Patients who were abstinent from
heroin received 0.1 mg more (95% conﬁdence interval: 0.06–
0.14 mg) for each day they remained in treatment. For each
point change on the counselor’s tendency to encourage
dosage reduction scale, patients received 7.4 mg (95%
conﬁdence interval:  10.5 to  4.2 mg) less methadone while
Table 1. Associations between Potential Opioid Tolerance-Related Factors and the Methadone Dose at Which Patients Achieved
Heroin Abstinence
Variable Factor Sample
Mean n ¼ 168
Standard
Deviation
Association
with Effective
Methadone Dose
p-Value
Demographic Age 49.8 7.2  0.143 0.065
Gender (0 ¼ female, 1 ¼ male) 0.98 0.133 0.023 0.776
Drug use severity from ASI 0.290 0.113 0.042 0.587
Medical severity from ASI 0.477 0.371 0.058 0.456
Psychological severity from ASI 0.268 0.258 0.111 0.157
Quantity and frequency of use Number of days of heroin use in the last 30 d 21.52 12.04 0.008 0.923
Number of years of heroin use 18.59 11.33 0.056 0.474
Estimated amount of heroin used per day
(cocaine removed) in grams
18.97 26.55  0.079 0.359
Average local purity of heroin 0.259 0.140  0.238 0.002
Withdrawal experience Number of previous drug detoxifications 3.24 4.77 0.140 0.072
Number of previous alcohol detoxifications 0.54 2.07 0.029 0.714
Individual differences Self-reported family history of substance use
problems (0 ¼ no, 1 ¼ yes)
0.479 0.501 0.006 0.934
Diagnosis of pain disorder (0 ¼ no, 1 ¼ yes) 0.399 0.491 0.033 0.668
Severity of pain in last 4 wk (0–6 scale) 3.30 1.49  0.026 0.744
Diagnosis of PTSD (0 ¼ no, 1 ¼ yes) 0.310 0.463 0.347 ,0.001
Diagnosis of anxiety disorder but not PTSD
(0 ¼ no, 1 ¼ yes)
0.101 0.302 0.046 0.556
Self-reported emotional, physical, or sexual abuse
in last 30 d (0 ¼ no, 1 ¼ yes)
0.078 0.269 0.013 0.865
Self-reported emotional, physical, or sexual abuse
in lifetime (0 ¼ no, 1 ¼ yes)
0.527 0.500 0.063 0.418
Diagnosis of depression (0 ¼ no, 1 ¼ yes) 0.315 0.466 0.327 ,0.001
Self-reported depression in last 30 d (0 ¼ no, 1 ¼ yes) 0.410 0.493 0.185 0.017
Self-reported depression in lifetime (0 ¼ no, 1 ¼ yes) 0.600 0.490 0.107 0.167
Diagnosis of schizophrenia (0 ¼ no, 1 ¼ yes) 0.107 0.310 0.131 0.090
Treatment Guideline adherence (0 ¼ low, 1 ¼ high) 0.64 0.48 0.433 ,0.001
Days receiving methadone maintenance 309.2 107.7 0.375 ,0.001
Number of counseling visits 50.0 56.4 0.352 ,0.001
Tendency to encourage dose reductions 7.35 1.20  0.368 ,0.001
Treatment satisfaction (out of 32) 26.5 6.2 0.067 0.431
Pearson’s correlation coefficients are reported for continuous variables, and point biserial correlation coefficients are reported for categorical variables.
DOI: 10.1371/journal.pmed.0030080.t001
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for 42.3% of the variance in the dosage of methadone at
which patients abstained.
Adding common predictive variables to the model did not
alter the overall ﬁndings of the above model. Age, race,
baseline medical severity, or baseline substance use severity
did not signiﬁcantly predict effective methadone dosage (p
..10) and did not eliminate the signiﬁcance of the predictive
value of the other six variables.
Discussion
Dosing Curves
Individual patients’ opioid substitution medication needs
vary greatly, a fact that is often overlooked in treatment
research. The dosages typically tested in randomized trials of
methadone maintenance to date are below the dosage needed
to achieve abstinence in patients at the high end of the dose
response curve [1,3,4,6]. Thus, higher dosage conditions in
trials almost always produce better outcomes on average than
do lower dosage conditions.
The cumulative dose-response curve lends credence to
clinicians’ insistence that methadone dosing guidelines do
not apply to all patients. Fully 40% of patients in this study
maintained heroin abstinence on less than the recommended
60 mg methadone per day. Nevertheless, the importance of
adequate dosing is obvious, as the slight leftward shift of the
methadone dosage histogram in low guideline-adherent sites
was associated with signiﬁcantly greater heroin use among
patients. These data suggest that clinicians should be allowed
signiﬁcant ﬂexibility in methadone dosing as long as out-
comes are positive because extremely low dosages (2 mg/d)
may be effective in some patients, while others require
extremely high dosages (over 160 mg/d) to abstain from
heroin. Minimum dosage requirements are not necessary;
however, clinicians must recognize that a subset of patients
will be underdosed at dosages as high as 140 mg/d. Dosage
titration utilizing drug screening to measure dosage effective-
ness should facilitate the determination of appropriate
dosages for individual patients.
Individual Factors
Our analysis of factors related to opioid tolerance can
inform clinicians’ predictions of individual patients’ meth-
adone needs. First, these results suggest several possibly
counterintuitive practices relating to patients’ opioid use
history. Although it may seem logical to expect patients who
used lesser amounts or less pure heroin to need lower dosages
of methadone, this expectation is not supported by our data.
The amount of heroin used per day did not predict effective
methadone dosage, and living in an area with lower average
local heroin purity predicted need for higher methadone
dosages. It cannot be assumed that patients who became
dependent using lower dosages of heroin will need lower
dosages of methadone to achieve abstinence.
Ibuki et al. [12,13] hypothesized that excessive neuronal
ﬁring during opioid withdrawal facilitates signaling through
opioidergic pathways; this sensitization may later manifest as
tolerance to the effects of opioids. This theory predicts the
counterintuitive result identiﬁed here that repeated opioid
detoxiﬁcations increase tolerance to opioids. This may also
explain the ﬁnding that low local heroin purity is associated
with greater methadone needs. Assuming those using less
pure heroin achieve lower blood levels of opioid with each
use, users in areas with low local heroin purity would
experience withdrawal more quickly after each use and thus
more frequently over time.
Willenbring and colleagues [29] observed that methadone
clinics with low patient turnover and a large number of
patients who had been maintained stably in treatment for
years had successful treatment outcomes on lower average
methadone dosages. Keeping patients on stable opioid
dosages and limiting periods of withdrawal (e.g., repeated
attempts to cease or reduce methadone use) may reduce
development of opioid tolerance and allow for successful
long-term treatment of opioid dependence with low dosages
of methadone. These results suggest that maintaining a
patient on a dosage at which he or she experiences
withdrawal symptomatology late in the dosage cycle, or
repeatedly attempting to withdraw a patient from metha-
done, will not limit the need for methadone and may in fact
increase the dosage of methadone needed to achieve
abstinence over the long term.
Although it has been reported that some opioid substitu-
tion treatment clinics provide more methadone to their
patients with chronic pain [30], this did not appear to be
necessary to improve abstinence rates in our sample. Even
though chronic pain may be treated with opioid therapy,
patients with higher pain levels did not require more
methadone to abstain from heroin use.
In contrast, having a diagnosis of depression or PTSD was a
strong predictor of need for higher dosages of methadone.
Our results suggest that patients with these conditions should
be expected to require higher medication dosages, and thus,
it may make sense to more aggressively titrate dosages early in
treatment in these patients.
Treatment Delivery Factors
Although treatment factors are less likely to explain
individual differences in methadone dosage needs, they likely
inﬂuence who receives an adequate dosage to achieve
abstinence. Treatment factors that result in reduced like-
lihood of receiving an adequate dosage will bias the
population that achieved abstinence toward those who
require lower methadone dosages. Thus, dropping out of
treatment at an earlier time and attending a clinic that
encourages dosage reductions is associated with lower
effective methadone doses. We believe that only those
patients with low tolerance to methadone achieve abstinence
early in treatment or when clinicians encourage reductions in
dosages. Encouraging rapid dose titration early in treatment
and discouraging attempts at dosage reduction or cessation
should improve the percentage of patients who achieve
abstinence.
Limitations of This Study
The results reported in this study are predictive associa-
tions, but causation cannot be assumed. Also, the clinics
participating in this study treated few women and younger
patients. This may limit generalizability of the results.
Although including patients who received LAAM during
treatment did not change the study results, our analysis is not
sufﬁcient to conclude that the results of this study can be
generalized to opioid medications other than methadone
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observational, we cannot know that the dosage a patient
received while abstinent was the minimal dosage required for
abstinence. Some patients might have maintained abstinence
on lower dosages.
Future Directions
We suggest that future treatment research investigate
processes of dosage determination rather than speciﬁc drug
dosages (e.g., compare two treatment strategies; see [31] for
an example). When there is large variation in individual dose-
response relationships, overall dosage-level recommenda-
tions may not provide clinicians with sufﬁcient information
to guide treatment practice. We suggest that research that
identiﬁes the most effective process for determination of
medication dosage may be more effectively translated into
clinical practice.
Summary
The range of effective methadone doses for treatment of
opioid dependence is broad, and treating clinicians should
titrate doses to full effect in each individual patient. Dosing
guidelines should include advice on appropriate processes of
dosage determination. Patients with PTSD, depression,
numerous prior opioid detoxiﬁcation treatments or with-
drawal episodes, and those who use low-purity heroin are
likely to require higher dosages of methadone to achieve
abstinence.
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Determining Individual Methadone DosesPatient Summary
Background. Methadone is a legal and rigorously tested synthetic drug
that acts on the same brain targets as heroin. Because methadone lasts a
lot longer in the body than heroin, patients on methadone do not
experience the extreme highs and lows that are felt by people who use
heroin (the highs and lows result from the waxing and waning of heroin
levels in the blood). Methadone has been used for more than 30 years to
help patients overcome heroin addiction. If patients take methadone as
prescribed, they are unlikely to get withdrawal symptoms when they
stop taking heroin, or the withdrawal symptoms are much less severe.
Additionally, methadone blocks the high produced by heroin so that
taking heroin is no longer rewarding. Patients on methadone remain
physically dependent on the drug, but most of them no longer have the
uncontrolled, compulsive, and disruptive behavior caused by heroin
addiction. Prolonged methadone treatment under medical supervision
has been shown to be safe, and it allows patients to lead ‘‘normal’’ lives
while taking a daily dose of methadone.
Why Was This Study Done? In many studies over the past decade or so,
researchers have tried to determine which methadone dosages work
best to help patients overcome heroin addiction. Based on these studies,
dosages of at least 60 mg/day are recommended. That said, doctors in
methadone clinics often see a wide range of dosages that are effective,
and some of them treat patients with dosages that are lower or higher
than the recommended amount. In this study, the researchers examined
the range of methadone dosages that helped patients achieve heroin
abstinence. They also wanted to find factors that influenced whether a
particular patient needed a higher or a lower dosage.
What Did the Researchers Do and Find? They studied 222 heroin-
addicted volunteers who started methadone treatment and followed
them for a year. Of these, only 168 achieved at least one month of heroin
abstinence. The range of effective methadone dosages (among the
patients who achieved abstinence) was very wide, from 1.5 mg to 191.2
mg. Thirty-eight percent of the patients achieved abstinence on less than
60 mg, and 16% of the abstinent patients received a dosage of over 100
mg. On the other hand, almost half of the patients who did not achieve
heroin abstinence received the recommended dosage of 60 mg or more
methadone. Overall, patients at clinics that generally adhered to the
treatment guidelines (and treated most patients at 60 mg or higher)
were more likely to achieve abstinence. Among patients who achieved
abstinence, higher methadone doses were correlated with posttraumatic
stress disorder, depression, a higher number of previous detoxifications
from heroin, and some other factors.
What Does This Mean? This study confirms that effective methadone
doses (as defined by heroin abstinence for at least a month) vary very
widely. It shows that even high dosages that work for one patient may
be too low for another patient and that a substantial fraction of patients
achieve abstinence on less than the recommended dosage. The results
also suggest that there are some factors that might predict whether a
patient is more likely to need a higher dosage, such as a diagnosis of
posttraumatic stress disorder or depression. Most surprisingly, the results
suggest that attempts to stop using methadone may actually increase
the need for methadone over the long term. It seems therefore
reasonable that doctors monitor the effects of treatment in each
individual patient to find the most effective dose for that individual.
However, as patients in clinics that adhere to the guidelines do better on
average, the recommended dose should serve as a benchmark that
might be adjusted upward or downward.
Where Can I Find More Information Online? The following Web sites
contain information on methadone therapy for heroin addiction.
MedlinePlus:
http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682134.
html
Omni:
http://omni.ac.uk/browse/mesh/D008691.html
American Association for the Treatment of Opioid Dependence:
http://www.aatod.org
Fact sheet on methadone from the US government: http://www.
whitehousedrugpolicy.gov/publications/factsht/methadone
UK Web site on addiction:
http://www.recovery.org.uk/druginfo/index.html
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